The GNRH1 Knockout KYSE-30 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human esophageal squamous cell carcinoma cell line KYSE-30, with targeted disruption of the GNRH1 gene. This product provides a heterogeneous pool of cells carrying a range of gene-editing events, serving as a loss-of-function model for functional studies of gonadotropin-releasing hormone (GnRH) in cancer biology. The polyclonal format captures diverse genetic modifications without clonal selection, enabling robust assessment of gene function in a cancer-relevant context.
The host cell line KYSE-30 was established from a well-differentiated invasive esophageal squamous cell carcinoma and is widely used to study esophageal cancer pathogenesis. These cells retain key epithelial characteristics and invasive properties, making them suitable for investigating molecular mechanisms underlying tumor cell proliferation, migration, and therapeutic response in vitro.
GNRH1 encodes the preprohormone that is processed to gonadotropin-releasing hormone (GnRH). In the neuroendocrine axis, GnRH acts through its receptor GNRHR on pituitary gonadotrophs, activating Gq/11-coupled signaling that mobilizes calcium and stimulates the MAPK/ERK cascade, leading to synthesis and secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This pathway is regulated by upstream factors such as kisspeptin (KISS1) and neurokinin B (TAC3), and feedback from sex steroids. In extra-pituitary tissues, the GnRH/GNRHR system can operate in an autocrine/paracrine manner, engaging phospholipase C, IP3, DAG, protein kinase C, and ERK to influence cell behavior.
Disruption of GNRH1 in KYSE-30 cells allows direct interrogation of local GnRH signaling in esophageal squamous cell carcinoma. Many cancers express ectopic GnRH and its receptor, which may modulate proliferation, migration, and apoptosis. This knockout model enables dissection of endogenous GnRH contributions to KYSE-30 cell dynamics and provides a platform to evaluate the specificity of GnRH receptor antagonists under investigation for hormone-dependent cancers.
Typical applications include investigating the role of autocrine GnRH loops in esophageal cancer progression, drug screening for GnRH pathway modulators, and exploring crosstalk with growth factor signaling. Knockout validation can be performed by Sanger sequencing and RT-qPCR, with downstream analysis via western blot for phospho-ERK, MTS or BrdU proliferation assays, Transwell migration/invasion assays, and flow cytometry for cell cycle or apoptosis. Co-culture with pituitary cells permits ELISA-based assessment of LH and FSH release, while reporter assays detect GnRH-responsive transcription. For further details, please contact Ascent Research.
